Join
Codiak BioSciences Inc. logo

CDAK

NASDAQ

Codiak BioSciences Inc.

SectorHealth CareIndustry Medicinal Chemicals and Botanical Products IPO2020
$0.06-0.07 (-53.11%)
News25/Ratings2

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest news

25 items

CDAK FAQ

7 questions
  • What does Codiak BioSciences Inc. do?
    Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for...
  • Where does CDAK stock trade?
    Codiak BioSciences Inc. (CDAK) is listed on NASDAQ.
  • What sector and industry is CDAK in?
    Codiak BioSciences Inc. operates in the Health Care sector, Medicinal Chemicals and Botanical Products industry.
  • When did Codiak BioSciences Inc. go public?
    Codiak BioSciences Inc. (CDAK) completed its IPO in 2020.
  • What are analysts saying about CDAK?
    Codiak BioSciences Inc. has had 2 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $2400.00 price target on 2022-02-22. Recent price targets range from $1900.00 to $2400.00.
  • What companies are similar to CDAK?
    Notable peers in the same industry include PM (Philip Morris International Inc), BTI (British American Tobacco Industries p.l.c.), MO (Altria Group Inc.), RGC (Regencell Bioscience Holdings Limited), RLX (RLX Technology Inc.). Compare CDAK side-by-side with any of them on Quantisnow.
  • How can I track CDAK on Quantisnow?
    Quantisnow aggregates Codiak BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDAK to receive live email and push alerts on every new disclosure.